复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场

财中社2025-12-30

12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。　　该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。截至2025年11月，集团针对SRT-007的累计研发投入约...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595795784?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-30 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595795784","market":"sh","top_or_hot":-1,"title":"复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场","media":"财中社","content":"<div>\n<p>12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。　　该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。截至2025年11月，集团针对SRT-007的累计研发投入约...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202512303605800274.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药启动SRT-007临床试验 3219万元研发投入瞄准13.92亿美元市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-30 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202512303605800274.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。　　该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。截至2025年11月，集团针对SRT-007的累计研发投入约...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202512303605800274.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"http://finance.eastmoney.com/a/202512303605800274.html","article_id":"2595795784","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595795784","pubTimestamp":1767088986,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","BK1593":"医美概念股","SRT":"Startek Inc","BK0196":"行业龙头","BK0175":"白马股","BK4106":"数据处理与外包服务","BK0188":"融资融券","BK4226":"数据处理及外包服务","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0096":"民营医院","BK0183":"MSCI概念","BK1515":"抗疫概念","BK1191":"制药"},"translate_title":"Fosun Pharma launches SRT-007 clinical trial, investing 32.19 million yuan in R&D, targeting the market of US $1.392 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5,"SRT":1.5},"content_text":"12月30日，复星医药（600196/02196）发布公告，控股子公司成都星睿菁烜生物科技有限公司已于近期在中国境内启动了诊疗一体化核药项目SRT-007的Ⅰ期临床试验，适应症为PSMA阳性的转移性去势抵抗性前列腺癌的诊断和治疗。　　该项目包括镓[68Ga]PSMA-0057（诊断）和镥[177Lu]PSMA-0057（治疗）两个注射液。截至2025年11月，集团针对SRT-007的累计研发投入约为3219万元（未经审计；包含许可费）。　　全球范围内已获批上市的同靶点放射性药物为NOVARTIS AG的Pluvicto，2024年其全球销售额为13.92亿美元。　　2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595795784","isCrawlerRequest":true}